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GLOBAL AGREEMENT ON
AITRNATE
TESTING
In recent years, public pressure in
the United States and abroad, COU-
pled with advances in science and
technology, have led to a radical
reevaluation of the longtime and
widespread use ofanimals in tOX-
icological experiments. As a
result, new testing methods
designed to refine, reduce, and
replace animal models have
emerged in government, aca-
demic, and industry labora-
tories worldwide. But this
sudden shift has left both
researchers and regulators
scrambling to determine
when the results from
alternative test methods
are valid and acceptable and
when they are not.
"It's a small world," says Neil Wilcox,
special assistant to the associate comnmis-
sioner for science at the Food and Drug
Administration. "The scientific community
and changes in toxicity testing are now
international in scope. Everything we do
has international implications and whatev-
er we do impacts the international comn-u-
nity. Harmonization will reduce the waste-
ful duplication of efforts by standardizing
testing."
The search for a set of internationial
standards began in earnest five years ago
when the European Union (EU) created
the European Center for the Validation
of Alternative Methods (ECVAM).
ECVAM's principal role is to coordinate
the validation of alternative methods
among the EU's 15 member states. As early
as 1987, the global Organization for
Economic Cooperation and Development
(OECD) began to consider animal welfare
issues in its international guidelines for the
testing of chemicals. And in 1994 in the
United States, the NIEHS established the
Interagency Coordinating Committec of
Criteria on the Validation of Alternative
Methods (ICCIVAM) with a goal ofaclhiev-
ing domiiestic and initernatiotnal harmloniiza-
tion of criteria for the validationi anid
acceptance of suchI methlods. Today, the
three groups are workinig together to bring
scientific laboratories and regulatory agen-
cies into agreemenet oni alternative test
guidelines.
"Thle challenige is to comiie up with use-
ful criteria for scientists in any counltry
who are developing tnew m1ethods," says
Williaim Stokes, associate director for ani-
mal antd alterniative resources at the
NIEHS and cochair of ICCVAM. "Tlhey
muist meet criteria tlhat would be the samiie
internationally. It wVouldn't make senise for
one counatry tO conlsider a test metlhod valid
while aniother didIn't. Ealch new msethod
Imlust bc relilblc, relevant, anid repirodLucible
in dift-ferent laboratories. If vou getnerate a
new miiethlod, a comnpaniy will be reluctant
to use it if the data wonI't be acceptable to
the regulatory agenicies ill the internationial
marketplace. In the development and vali-
dation of alternitive miethiods for acute
toxicity, the Etiropeanis liave been pursu-
ing a mnore focused effort anid we're very
initerested in followinig the results of
their work."
Thlle EU issued a directive in 1986
discouraging sclenitists in its meumber
states froml USing animtals if they
could reasotnably anid practicably
aclieve the saimle reesult without ani-
niials. "EU legislatiotn requires that
inonianimiail test imiethlods be used
whieniever possible, and that efforts
are made to develop and validate
suchI imethods," says Michael
Balls, head of ECVAM. "TIhe
mialin obstacles are sclenitific and
adminlistrative. [For exa.mple],
the developmiienit and validation
of relevanit antd reliable alterna-
tive methodis is difficult [and]
regulatory authorities tend to
adopt a coiiservative stanice and feel more
cornifortable with aniimial test data.'
Because wvell-establishcd animal tests
have set the stanidard for decades, success-
fully replacing tlhetmi will be a challenige.
Alternative imetlhods miiay feature the use of
microbes, cells, tissuces, andt othier in vitro
mzethods, or rely inistead onl coIImputer data-
bascs and miiatlhemliatical imiodels. Otther new
methiods m1ay involye uLse of genietically
enginieered anitials or lower species.
Revised methoIs may in1c-lude modifica-
tiolns that re(liir-e fewer animnals or mini-
mize or eliminlate animial paini and distress.
If interniationial hiarmiionizationi is achieved,
each interested country's laboratories and
regulatory agencies will accept the results
of new or revised tests, includinig nonianii-
mal tests.
For instanice, as companies expand into
overseas markcts, their products ImiUst tmilet
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the regulatory guidelines of each country
to which they want to export. At the
moment, many countries have their own
guidelines, which may differ from those of
other countries. With this ad hoc process,
companies risk the loss of potential mar-
kets or the heavy expense of additional
tests. For example, nonanimal test results
of a product that might be acceptable in
one country might be rejected in another
for the same reason: because the test meth-
ods did not include animals.
"Harmonization helps us significant-
ly," says Katherine Stitzel, associate direc-
tor of the human safety department at
Procter & Gamble. "In a global company
that's working across borders, it saves us
animals, time, and money. It's a drag on
our resources to have to do things differ-
ently for different countries. It will make
things so much easier when everyone is in
agreement.
An International Platform
Founded in 1960 to stimulate economic
progress and world trade and promote
social welfare, OECD membership now
includes 26 countries including most
European countries, as well as the United
States, Mexico, Canada, Australia, New
Zealand, and Japan. With its global reach,
the OECD has become a major player in
the quest for international harmonization.
"The OECD is a unique forum for
countries with advanced market
economies," says Herman Koeter, principal
administrator at the OECD's environmen-
tal health and safety division based in
Paris. "Until the early 1990s, our role in
alternative test methods was to accept
applications and distribute them to our
members for comments and approval. But
we gradually began to realize that
approaches to validation were not exactly
the same in Europe and elsewhere. So in
1991, OECD decided to take a more
active role in encouraging nonanimal test-
ing by bringing members together to nego-
tiate, discuss, and arrive at a consensus.
In 1987 and in 1992, the OECD
issued guidelines for skin and eye testing
that examined for the first time the possi-
bility of using alternative, nonanimal
methods for testing chemicals. At the time,
however, the guidelines acknowledged that
many tests were not ready to be conducted
solely in vitro, especially those that assess
the potential for skin sensitization.
Accurate results, the guidelines said, could
still only be achieved through standard in
vivo testing.
In January 1996, the OECD organized
aworkshop in Stockholm, Sweden, on tox-
icological test alternatives to discuss inter-
national harmonization of validation and
regulatory acceptance criteria for alterna-
tive tests. The ICCVAM draft report,
ECVAM documents, and documents from
other animal welfare centers were used as
the basis for discussion. The draft ICC-
VAM report was developed by 15 U.S.
federal scientific and regulatory agencies.
At the workshop, participants agreed on
test strategies for skin and eye tests "where
schemes could be made mandatory," says
Koeter. "When we discussed different
approaches member-country-wide, there
were no principal differences. Science and
safety remain the keyelements."
"One of the recommendations from
the workshop was that developers of new
methods should contact the appropriate
regulatory agencies during the develop-
ment and validation stages in order to opti-
mize the usefulness of test methods," says
Stokes. "This way, they can make changes
in their method early on. You need a phase
where you optimize the test protocol prior
to formal validation studies."
Another workshop recommendation
was to allow the use ofpatented methods,
according to Stokes. Patented methods
"may be necessary to stimulate creativity
and innovation," he says. Currently,
OECD guidelines do not permit patent-
ed methods because some countries may
not be able to run the tests if such
patented expertise and materials are diffi-
cult to acquire. In addition, Koeter said,
adopting a patented test from one com-
pany as an OECD guideline may put the
OECD in the position of providing that
company with an unfair advantage over
its competitors.
The OECD will present the workshop
recommendations to the policy representa-
tives or national coordinators ofeach ofits
member countries. The formal adoption of
new methods, Koeter says, may take
months because each proposed method
will face legal, policy, and economic impli-
cations that must be addressed by each
country's governing body. In order to be
approved as an OECD guideline, each pro-
posal must be unanimously approved by its
member states.
After two years of discussions and
negotiations, the OECD member states
approved an alternative test method as an
OECD guideline at the beginning of this
year. Called the acute toxic class method,
this alternative approach allows for a sig-
nificant reduction in the number of ani-
mals required in acute oral toxicity tests.
The test allows for the use of as few as
three animals-"a fraction of the original
amount," says Koeter. He also notes,
"Sometimes it's easier to modify an exist-
ing guideline by adding new text in line
with animal welfare. For example, an in
vitro test could be recommended or even
required before an animal test can be per-
formed."
Modifying standard animal tests has
opened many new questions about what
constitutes an appropriate replacement.
"While some in vitro methods appear to be
useful for specific chemical classes, they are
not generally useful for all chemicals," says
Stokes. "You have to validate a method for
a specific purpose, which is often more
readilydone in a stepwise fashion."
"Regarding the use of rodent models,"
adds Wilcox, "it's not always clear where it
is adequate in different chemical classes.
For example, in some classes, a rat might
give 80% concordance or accuracy. But
what do you do for the other 20%? Do
you use a mouse model? Or should you use
alternatives, such as a transgenic model?
We still don't know ifit is possible to take
one rodent species and supplement it with
an alternative. It's a very complex scenario,
no question about it."
Harmony in Europe
Independent and neutral, ECVAM is part
of the European Union Joint Research
Center's Environment Institute in Ispra,
Italy. The center's scientific advisory com-
mittee includes representatives from the
member states of the EU as well as from
the chemical, cosmetic, and pharmaceuti-
cal industries and from animal welfare
groups. With no single EU-wide regulatory
agency, harmonization must be
approached industry by industry and coun-
try by country. But when agreements are
reached in the form ofEU directives, they
are binding on all the member states,
which must adapt their national legislation
to complywith the directive's provisions.
Within the EU, there is "a communal
commitment to the replacement ofanimal
tests as validated nonanimal tests and test-
ing strategies become available," says Balls.
"However, the strength of feeling on this
issue varies from country to country, as
would be expected. Germany, the
Netherlands, Sweden, and the UK are par-
ticularly committed to the reduction,
refinement, and replacement of animal
testing."
While ECVAM's principal role is to
coordinate the validation of alternative
methods at the EU level, its representatives
are active in all worldwide discussions on
harmonization. However, with 15 mem-
bers, the EU is also in a position to make
international progress on its own. In gener-
al, this could lead to tensions, says Balls,
but as far as alternative methods are con-
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cerned, "the existing good relations
between partners such as ECVAM, ICC-
VAM, and the OECD should help to
avoid that problem. There may be minor
differences, but only because ECVAM's
duty is to serve the European Commission
and the EU, whereas ICCVAM's primary
focus is the U.S. regulatory [and research]
agencies."
Harmony in the United States
Similar in concept to ECVAM, ICCVAM
also recommends processes acceptable to
15 U.S. scientific and regulatory agencies.
Mandated by the National Institutes of
Health Revitalization Act of 1993, ICC-
VAM consists of ad hoc representatives
from those agencies. Though its principal
mandate did not include international har-
monization, ICCVAM approached the
OECD to consider its criteria for valida-
tion and acceptance of new methods,
knowing that all testing methods approved
in the United States should also meet
international criteria for approval.
"ICCVAM agreed OECD should be
involved from the start to make it easier to
get acceptance internationally," says
Koeter. "Before finalizing its report, ICC-
VAM wanted OECD to take a look at it,
not as a bible, but as a basis for discussion.
As we determined at the Stockholm work-
shop there were no essential differences,
OECD will now develop a document close
to ICCVAM's. When it came to a way of
thinking, there was widespread acceptance
ofalternative tests."
"We're in the business of developing
and validating methods that would be
more useful for predicting environmental
health hazards," says Stokes. "As we learn
more at the molecular and cellular levels
about the mechanisms by which chemicals
cause toxicity, we can transform our
understanding into a mechanistic test
method. As we develop better test meth-
ods, the hope is that we can better predict
the toxicity of that chemical before it gets
into the environment, the workplace, or
the food supply, and before it can cause
adverse effects on human health."
It is generally agreed that the process of
harmonization will be lengthy, requiring
ongoing meetings and workshops. It may
take years to establish a universal set of
guidelines agreed upon by scientists and
regulators. But the results should dramati-
cally reduce the need for animals in toxico-
logical experiments while ensuring the
validity and acceptance ofsuch tests world-
wide.
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